Compare GSUN & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSUN | PRFX |
|---|---|---|
| Founded | 1997 | 2007 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 2.6M |
| IPO Year | 2020 | 2020 |
| Metric | GSUN | PRFX |
|---|---|---|
| Price | $0.21 | $0.88 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 934.4K | 258.6K |
| Earning Date | 08-19-2026 | 09-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.58 |
| 52 Week High | $2.83 | $5.39 |
| Indicator | GSUN | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 38.26 | 38.52 |
| Support Level | $0.17 | $0.60 |
| Resistance Level | $0.27 | $1.25 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 7.30 | 2.06 |
Golden Sun Technology Group Ltd operates two principal lines of business: tutorial services and e-commerce services. The company's e-commerce operations currently consist of data analytics-driven marketing and social media promotional services for small and medium-sized businesses on short video platforms based in China. The company's education centers offer two main programs, comprising of foreign language tutorial programs in less commonly taught languages, including, among other things, Spanish and Japanese, provided to individual students as well as to companies and other organizations; and Gaokao repeater tutorial programs, provided to individual students.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.